Literature DB >> 12144935

Plasma catecholamines in ethanol tolerance and withdrawal in mice.

Gábor L Kovács1, Márta Soroncz, István Tegyei.   

Abstract

Plasma levels of catecholamines (noradrenaline and adrenaline) as well as the ratio of the two catecholamines were measured in experimental mice during various stages of acute and chronic ethanol treatment. Acute intraperitoneal (i.p.) ethanol administration and acute per os (p.o.) ethanol ingestion resulted in a similar elevation of the plasma levels of both catecholamines. During the development of ethanol tolerance/dependence (ingestion of drinking water containing ethanol for 14 days), plasma catecholamine concentrations returned to the control levels. During subsequent ethanol withdrawal, a highly significant increase was observed in plasma noradrenaline. The withdrawal-associated elevation of plasma adrenaline was also significant; however, the rise in plasma noradrenaline during withdrawal appeared to be higher than that found for adrenaline. Thus, the ratio of plasma noradrenaline to adrenaline was higher during withdrawal, and this ratio also exhibited an association with the severity of ethanol withdrawal symptoms. Since plasma noradrenaline derives to a great extent from the sympathetic nervous system--and the alcohol withdrawal syndrome is characterized by symptoms of overactivity of this system--a positive correlation may exist between noradrenaline and the severity of withdrawal symptomatology. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12144935     DOI: 10.1016/s0014-2999(02)01939-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  CRF modulation of central monoaminergic function: Implications for sex differences in alcohol drinking and anxiety.

Authors:  Kristen E Pleil; Mary Jane Skelly
Journal:  Alcohol       Date:  2018-02-02       Impact factor: 2.405

2.  A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder.

Authors:  Tracy L Simpson; Carol A Malte; Bergetta Dietel; Dana Tell; Ian Pocock; Robert Lyons; Dana Varon; Murray Raskind; Andrew J Saxon
Journal:  Alcohol Clin Exp Res       Date:  2015-04-01       Impact factor: 3.455

Review 3.  Noradrenergic targets for the treatment of alcohol use disorder.

Authors:  Carolina L Haass-Koffler; Robert M Swift; Lorenzo Leggio
Journal:  Psychopharmacology (Berl)       Date:  2018-02-20       Impact factor: 4.530

4.  A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder.

Authors:  Claire E Wilcox; J Scott Tonigan; Michael P Bogenschutz; Joshua Clifford; Rose Bigelow; Tracy Simpson
Journal:  J Addict Med       Date:  2018 Sep/Oct       Impact factor: 3.702

Review 5.  Noradrenergic circuits and signaling in substance use disorders.

Authors:  Anthony M Downs; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2022-02-14       Impact factor: 5.273

6.  The peripheral dopamine 2 receptor antagonist domperidone attenuates ethanol enhancement of dopamine levels in the nucleus accumbens.

Authors:  James Daniel Obray; Eun Young Jang; Anneke M Klomp; Christina A Small; Aaron P Richardson; Joshua J LeBaron; Jin Gyeom Lee; Jordan T Yorgason; Chae Ha Yang; Scott C Steffensen
Journal:  Alcohol Clin Exp Res       Date:  2022-02-01       Impact factor: 3.455

Review 7.  Elevated Norepinephrine may be a Unifying Etiological Factor in the Abuse of a Broad Range of Substances: Alcohol, Nicotine, Marijuana, Heroin, Cocaine, and Caffeine.

Authors:  Paul J Fitzgerald
Journal:  Subst Abuse       Date:  2013-10-13

8.  Circulating catecholamines are associated with biobehavioral factors and anxiety symptoms in head and neck cancer patients.

Authors:  Daniela B Bastos; Bruna A M Sarafim-Silva; Maria Lúcia M M Sundefeld; Amanda A Ribeiro; Juliana D P Brandão; Éder R Biasoli; Glauco I Miyahara; Dulce E Casarini; Daniel G Bernabé
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

9.  Predisposing factors for increased cortisol levels in oral cancer patients.

Authors:  Jéssica Araújo Figueira; Bruna Amélia Moreira Sarafim-Silva; Gislene Maria Gonçalves; Laerte Nivaldo Aranha; Flávia Lombardi Lopes; José Eduardo Corrente; Éder Ricardo Biasoli; Glauco Issamu Miyahara; Daniel Galera Bernabé
Journal:  Compr Psychoneuroendocrinol       Date:  2022-01-06

Review 10.  Mechanisms of Shared Vulnerability to Post-traumatic Stress Disorder and Substance Use Disorders.

Authors:  Cristina E María-Ríos; Jonathan D Morrow
Journal:  Front Behav Neurosci       Date:  2020-01-31       Impact factor: 3.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.